Compare Pfizer with Cipla - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

PFIZER vs CIPLA - Comparison Results

PFIZER     Change

Pfizer India is a 71% subsidiary of the world's largest pharmaceuticals company Pfizer Inc. Pfizer derives a larger share of its revenues from the pharmaceuticals division (81%). The company also has presence in the animal health (13%) and clinical d... More

CIPLA 
   Change

Cipla is one of the largest pharma companies in the domestic market and has presence in formulations and bulk drugs manufacturing. All the bulk drug manufacturing facilities of the company have been approved by various authorities including the US FD... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    PFIZER CIPLA PFIZER/
CIPLA
 
P/E (TTM) x 33.1 23.6 140.1% View Chart
P/BV x 5.5 2.4 229.9% View Chart
Dividend Yield % 0.6 0.7 92.3%  

Financials

 PFIZER   CIPLA
EQUITY SHARE DATA
    PFIZER
Mar-18
CIPLA
Mar-19
PFIZER/
CIPLA
5-Yr Chart
Click to enlarge
High Rs2,365678 348.8%   
Low Rs1,625484 335.9%   
Sales per share (Unadj.) Rs430.3198.2 217.1%  
Earnings per share (Unadj.) Rs78.718.5 424.9%  
Cash flow per share (Unadj.) Rs93.235.0 266.4%  
Dividends per share (Unadj.) Rs20.003.00 666.7%  
Dividend yield (eoy) %1.00.5 194.1%  
Book value per share (Unadj.) Rs586.5186.3 314.8%  
Shares outstanding (eoy) m45.75805.70 5.7%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x4.62.9 158.2%   
Avg P/E ratio x25.331.4 80.8%  
P/CF ratio (eoy) x21.416.6 128.9%  
Price / Book Value ratio x3.43.1 109.1%  
Dividend payout %25.416.2 156.9%   
Avg Mkt Cap Rs m91,271468,031 19.5%   
No. of employees `0002.622.6 11.6%   
Total wages/salary Rs m3,14328,565 11.0%   
Avg. sales/employee Rs Th7,484.87,053.1 106.1%   
Avg. wages/employee Rs Th1,195.01,261.5 94.7%   
Avg. net profit/employee Rs Th1,369.1659.1 207.7%   
INCOME DATA
Net Sales Rs m19,685159,710 12.3%  
Other income Rs m1,1434,766 24.0%   
Total revenues Rs m20,828164,475 12.7%   
Gross profit Rs m5,00330,973 16.2%  
Depreciation Rs m66313,263 5.0%   
Interest Rs m41,684 0.2%   
Profit before tax Rs m5,47920,791 26.4%   
Minority Interest Rs m0-172 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,8785,695 33.0%   
Profit after tax Rs m3,60114,924 24.1%  
Gross profit margin %25.419.4 131.0%  
Effective tax rate %34.327.4 125.2%   
Net profit margin %18.39.3 195.7%  
BALANCE SHEET DATA
Current assets Rs m24,167124,266 19.4%   
Current liabilities Rs m9,54437,715 25.3%   
Net working cap to sales %74.354.2 137.1%  
Current ratio x2.53.3 76.8%  
Inventory Days Days5591 60.8%  
Debtors Days Days2995 30.3%  
Net fixed assets Rs m9,514105,190 9.0%   
Share capital Rs m4581,611 28.4%   
"Free" reserves Rs m26,375148,511 17.8%   
Net worth Rs m26,832150,123 17.9%   
Long term debt Rs m2538,301 0.1%   
Total assets Rs m36,900239,633 15.4%  
Interest coverage x1,305.513.3 9,783.6%   
Debt to equity ratio x00.3 0.4%  
Sales to assets ratio x0.50.7 80.0%   
Return on assets %9.86.9 141.0%  
Return on equity %13.49.9 135.0%  
Return on capital %20.411.8 172.5%  
Exports to sales %034.7 0.0%   
Imports to sales %00-   
Exports (fob) Rs mNA55,419 0.0%   
Imports (cif) Rs mNANA-   
Fx inflow Rs m2257,410 0.0%   
Fx outflow Rs m1,48919,041 7.8%   
Net fx Rs m-1,46638,368 -3.8%   
CASH FLOW
From Operations Rs m3,31816,911 19.6%  
From Investments Rs m-2,383-16,687 14.3%  
From Financial Activity Rs m-1,104-3,487 31.6%  
Net Cashflow Rs m-169-3,451 4.9%  

Share Holding

Indian Promoters % 0.0 16.0 -  
Foreign collaborators % 63.9 20.8 307.2%  
Indian inst/Mut Fund % 7.5 12.2 61.5%  
FIIs % 4.9 23.7 20.7%  
ADR/GDR % 0.0 1.1 -  
Free float % 23.7 26.2 90.5%  
Shareholders   85,207 161,166 52.9%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare PFIZER With:   DR. DATSONS LABS  DISHMAN PHARMA  TTK HEALTHCARE  JUBILANT LIFE SCIENCES  BIOCON   

Compare PFIZER With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Slumps 470 Points; Energy and Banking Stocks Witness Selling(Closing)

Indian share markets witnessed negative trading activity throughout the day and ended deep in the red. The BSE Sensex fell over 550 points intraday and breached the 36,000 mark.

Related Views on News

CIPLA 2018-19 Annual Report Analysis (Annual Result Update)

Sep 9, 2019 | Updated on Sep 9, 2019

Here's an analysis of the annual report of CIPLA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of CIPLA. Also includes updates on the valuation of CIPLA.

CIPLA Announces Quarterly Results (1QFY20); Net Profit Up 5.6% (Quarterly Result Update)

Aug 13, 2019 | Updated on Aug 13, 2019

For the quarter ended June 2019, CIPLA has posted a net profit of Rs 5 bn (up 5.6% YoY). Sales on the other hand came in at Rs 40 bn (up 1.3% YoY). Read on for a complete analysis of CIPLA's quarterly results.

PFIZER Announces Quarterly Results (1QFY20); Net Profit Up 22.8% (Quarterly Result Update)

Aug 13, 2019 | Updated on Aug 13, 2019

For the quarter ended June 2019, PFIZER has posted a net profit of Rs 1 bn (up 22.8% YoY). Sales on the other hand came in at Rs 5 bn (up 6.3% YoY). Read on for a complete analysis of PFIZER's quarterly results.

PFIZER Announces Quarterly Results (4QFY19); Net Profit Up 4.7% (Quarterly Result Update)

May 29, 2019 | Updated on May 29, 2019

For the quarter ended March 2019, PFIZER has posted a net profit of Rs 1 bn (up 4.7% YoY). Sales on the other hand came in at Rs 5 bn (up 3.0% YoY). Read on for a complete analysis of PFIZER's quarterly results.

CIPLA Announces Quarterly Results (4QFY19); Net Profit Up 144.0% (Quarterly Result Update)

May 24, 2019 | Updated on May 24, 2019

For the quarter ended March 2019, CIPLA has posted a net profit of Rs 4 bn (up 144.0% YoY). Sales on the other hand came in at Rs 44 bn (up 19.1% YoY). Read on for a complete analysis of CIPLA's quarterly results.

More Views on News

Most Popular

Buy these 7 Stocks if You Believe in India(The 5 Minute Wrapup)

Sep 12, 2019

News headlines predict gloom and doom for India these days. You should ignore them.

A Recession Proof Stock You Can Bet On(Profit Hunter)

Sep 10, 2019

Usually, the typical horizon period for my smallcap recommendations is 3 to 5 years. But if you ask me, this could be one business that you could own and pass on to future generations.

A Rare Opportunity to Buy the Top 5 Stocks in the Market(The 5 Minute Wrapup)

Sep 16, 2019

The stock market today is throwing up a great opportunity to pile on quality stocks.

This Company Will Do Well Despite the Slowdown(The 5 Minute Wrapup)

Sep 11, 2019

How financial inclusion provides a big runway for this stock recommendation.

The 5 Best Trading Opportunities I've Spotted(Profit Hunter)

Sep 13, 2019

These 10 auto stocks should be in your watchlist for the next 32 months. Paste them on your workstation NOW.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

PFIZER SHARE PRICE


Sep 19, 2019 03:35 PM

TRACK PFIZER

COMPARE PFIZER WITH

MARKET STATS